<DOC>
	<DOCNO>NCT02521870</DOCNO>
	<brief_summary>This phase 1b/2 , open-label , multicenter trial design evaluate safety , tolerability , biologic activity , preliminary efficacy intratumoral SD 101 injection combination intravenous pembrolizumab patient metastatic melanoma recurrent metastatic head neck squamous cell carcinoma ( HNSCC ) . Phase 1 trial modify 3+3 dose escalation study evaluate escalate intermediate dose level SD-101 give fix dose pembrolizumab patient metastatic melanoma . Phase 2 study consist 4 expansion cohort evaluate efficacy safety SD-101 give combination pembrolizumab specific melanoma HNSCC population : For indication melanoma HNSCC 2 separate cohort recruit , anti-programmed death receptor-1/ligand 1 ( anti-PD-1/L1 ) therapy na√Øve progressive disease ( PD ) receive anti-PD-1/L1 therapy .</brief_summary>
	<brief_title>A Trial Intratumoral Injections SD-101 Combination With Pembrolizumab Patients With Metastatic Melanoma Recurrent Metastatic Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description>This study conduct two part . Phase 1b dose escalation patient test SD-101 various dos combination 200 mg pembrolizumab patient metastatic melanoma . Phase 2 consist 4 expansion cohort evaluate efficacy safety SD-101 give combination 200 mg pembrolizumab specific melanoma population recurrent metastatic HNSCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Phase 2 Melanoma patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Provide tissue PDL1 biomarker analysis newly obtain biopsy obtain within 28 day enrollment . Must adequate organ function indicate laboratory result . Histologically cytologically confirm unresectable intransit ( stage IIIc ) metastatic ( stage IV ) melanoma . At least 2 site measurable disease 1 must palpable visualized ultrasound easily accessible multiple intratumoral injection . The injected lesion must qualify measurable target lesion per RECIST 1.1 . Metastatic melanoma patient progressive disease ( PD ) receive antiPD1/L1 therapy must document PD per RECIST 1.1 receive prior antiPD1/L1 therapy must receive prior antiPD1/L1 agent within 6 week study enrollment . Phase 2 HNSCC patient Histologically cytologically confirm recurrent metastatic HNSCC could treat curative intent . Have least 1 measurable site disease ( target lesion per RECIST 1.1 , must accessible amenable multiple intratumoral injection . If superficial , lesion must measure least 10 mm diameter , measure caliper , document photographically . Recurrent metastatic HNSCC patient PD receive antiPD1/L1 therapy must document PD per RECIST 1.1 receive antiPD1/L1 therapy must receive antiPD1/L1 agent within 6 week study enrollment . ( Phase 2 Melanoma HNSCC patient ) Is expect require form anticancer therapy trial . Positive hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . History current uveal ocular melanoma . Active infection include cytomegalovirus . Active autoimmune disease require systemic treatment past 2 year disease require immunosuppressive medication include systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia . Replacement therapy ( eg , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency ) consider form systemic treatment . Current pneumonitis history ( noninfectious ) pneumonitis require steroid . Known active central nervous system metastases carcinomatous meningitis . Use investigational agent within last 28 day prior study enrollment . Has receive livevirus vaccination within 30 day plan treatment start . Seasonal flu vaccine contain live virus permit . Any known additional malignancy progress require active treatment , except melanoma HNSCC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Skin Cancer</keyword>
	<keyword>Skin Tumors</keyword>
	<keyword>Head Neck Squamous Cell Carcinoma</keyword>
	<keyword>Cancer Immunotherapy</keyword>
</DOC>